Novartis' Cosentyx Gives More Additional Benefit Than Stelara, Says German HTA
This article was originally published in Scrip
Executive Summary
Novartis AG's Cosentyx (secukinumab) offers some plaque psoriasis patients "considerable additional benefit" over Johnson & Johnson's Stelara (ustekinumab), says the G-BA, the body in charge of Germany's AMNOG benefit assessment and pricing process. The news means that Novartis should find it easier to argue a better price during negotiations with health insurers.
You may also be interested in...
Canada Counters Drug Shortages With Export Bans
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
The COVID-19 Economic Crisis – Fallout And Opportunities
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Need a specific report? 1000+ reports available
Buy Reports